Kailin Yu

544 total citations
18 papers, 238 citations indexed

About

Kailin Yu is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Kailin Yu has authored 18 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 6 papers in Genetics and 6 papers in Hematology. Recurrent topics in Kailin Yu's work include Chronic Lymphocytic Leukemia Research (6 papers), Chronic Myeloid Leukemia Treatments (4 papers) and RNA modifications and cancer (4 papers). Kailin Yu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Chronic Myeloid Leukemia Treatments (4 papers) and RNA modifications and cancer (4 papers). Kailin Yu collaborates with scholars based in China and United States. Kailin Yu's co-authors include Aoli Wang, Jing Liu, Qingsong Liu, Ziping Qi, Fengming Zou, Yinsheng Wang, Shanchun Zhang, Li Wang, Zongru Jiang and Beilei Wang and has published in prestigious journals such as Analytical Chemistry, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.

In The Last Decade

Kailin Yu

18 papers receiving 237 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kailin Yu China	11	167	64	55	37	31	18	238
Shengyong Yang China	13	187 1.1×	103 1.6×	73 1.3×	20 0.5×	31 1.0×	18	356
Deepa Bhavsar United States	7	155 0.9×	47 0.7×	73 1.3×	31 0.8×	17 0.5×	14	263
Joshua A. Ballard United States	5	148 0.9×	48 0.8×	26 0.5×	51 1.4×	19 0.6×	6	254
Andrew Conroy United States	5	165 1.0×	124 1.9×	60 1.1×	22 0.6×	46 1.5×	12	255
Sachie Otsuki Japan	5	143 0.9×	76 1.2×	50 0.9×	12 0.3×	14 0.5×	5	233
Patrícia Maciejewski United States	4	116 0.7×	43 0.7×	43 0.8×	79 2.1×	49 1.6×	9	282
Andiliy Lai United States	6	167 1.0×	44 0.7×	107 1.9×	54 1.5×	87 2.8×	7	336
Hiroyuki Moritomo Japan	7	231 1.4×	36 0.6×	134 2.4×	50 1.4×	14 0.5×	9	349
Minhao Huang China	10	197 1.2×	82 1.3×	121 2.2×	21 0.6×	18 0.6×	19	337
Daniel Kukral United States	8	105 0.6×	68 1.1×	61 1.1×	35 0.9×	23 0.7×	9	265

Countries citing papers authored by Kailin Yu

Since Specialization

Citations

This map shows the geographic impact of Kailin Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kailin Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kailin Yu more than expected).

Fields of papers citing papers by Kailin Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kailin Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kailin Yu. The network helps show where Kailin Yu may publish in the future.

Co-authorship network of co-authors of Kailin Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Kailin Yu. A scholar is included among the top collaborators of Kailin Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kailin Yu. Kailin Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Li, Lin, et al.. (2022). LC-MS/MS for Assessing the Incorporation and Repair of N²-Alkyl-2′-deoxyguanosine in Genomic DNA. Chemical Research in Toxicology. 35(10). 1814–1820. 4 indexed citations

Liu, Xiaochuan, et al.. (2022). Targeted Quantitative Profiling of Epitranscriptomic Reader, Writer, and Eraser Proteins Using Stable Isotope-Labeled Peptides. Analytical Chemistry. 94(37). 12559–12564. 7 indexed citations

Liu, Juan, Jingjing Gao, Aoli Wang, et al.. (2022). Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours. Molecular Oncology. 16(8). 1761–1774. 7 indexed citations

Cai, Qian, Lin Li, Kailin Yu, et al.. (2021). Modulation of N-terminal methyltransferase 1 by an N6-methyladenosine-based epitranscriptomic mechanism. Biochemical and Biophysical Research Communications. 546. 54–58. 10 indexed citations

Yu, Kailin, et al.. (2021). Quantitative proteomics revealed new functions of ALKBH4. PROTEOMICS. 22(7). e2100231–e2100231. 5 indexed citations

Yu, Kailin, et al.. (2020). Proteome-wide Interrogation of Small GTPases Regulated by N⁶-Methyladenosine Modulators. Analytical Chemistry. 92(14). 10145–10152. 10 indexed citations

Dong, Xuejiao, et al.. (2020). Chemical Proteomic Profiling of the Interacting Proteins of Isoprenoid Pyrophosphates. Analytical Chemistry. 92(12). 8031–8036. 3 indexed citations

Wang, Wenliang, Zongru Jiang, Li Wang, et al.. (2020). All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase. Cancer Letters. 473. 130–138. 7 indexed citations

Jiang, Zongru, Li Wang, Xuesong Liu, et al.. (2019). Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent. Acta Pharmaceutica Sinica B. 10(3). 488–497. 29 indexed citations

10.

Liu, Xuesong, Beilei Wang, Cheng Chen, et al.. (2019). Discovery of (E)-N¹-(3-Fluorophenyl)-N³-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). Journal of Medicinal Chemistry. 62(10). 5006–5024. 16 indexed citations

11.

Wang, Li, Chen Hu, Aoli Wang, et al.. (2019). Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models. Investigational New Drugs. 38(5). 1272–1281. 10 indexed citations

12.

Liang, Xiaofei, Cheng Chen, Zongru Jiang, et al.. (2018). Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. European Journal of Medicinal Chemistry. 156. 831–846. 12 indexed citations

13.

Chen, Yongfei, Kailin Yu, Aoli Wang, et al.. (2017). Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. European Journal of Medicinal Chemistry. 131. 107–125. 18 indexed citations

14.

Wang, Aoli, Xixiang Li, Hong Wu, et al.. (2017). Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode. Journal of Medicinal Chemistry. 60(7). 2944–2962. 28 indexed citations

15.

Hu, Chen, Aoli Wang, Hong Wu, et al.. (2017). Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget. 8(11). 18359–18372. 17 indexed citations

16.

Wang, Qiang, Feiyang Liu, Beilei Wang, et al.. (2016). Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. Journal of Medicinal Chemistry. 60(1). 273–289. 12 indexed citations

17.

Liu, Feiyang, Jinhua Wang, Xingxing Yang, et al.. (2016). Discovery of a Highly Selective STK16 Kinase Inhibitor. ACS Chemical Biology. 11(6). 1537–1543. 17 indexed citations

18.

Li, Xixiang, Aoli Wang, Kailin Yu, et al.. (2015). Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 58(24). 9625–9638. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact